Kanzonol W

Kanzonol W

SCHEMBL29378682

CC1(C)C=Cc2c(ccc3cc(-c4ccc(O)cc4O)c(=O)oc23)O1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.65
PTPN1 P18031 4/20 0.56
SOAT2 O75908 1/20 0.52
PDE4D Q08499 6/20 0.50
BCHE P06276 5/20 0.49
ACHE P22303 4/20 0.49
ALOX5 P09917 1/20 0.49
ALOX12 P18054 1/20 0.49
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
BACE1 P56817 1/20 0.49
PTPN22 Q9Y2R2 1/20 0.49
XDH P47989 1/20 0.47
LMNA P02545 1/20 0.46
IDO1 P14902 2/20 0.45
PDE2A O00408 1/20 0.45
PDE5A O76074 1/20 0.45
PDE9A O76083 1/20 0.45
PDE1B Q01064 1/20 0.45
PDE10A Q9Y233 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29377602 0.89 TYR (0.53) TYRPTPN1SOAT2PDE4DBCHE
SCHEMBL31090510 0.79 TYR (1.00) TYRPTPN1SOAT2PTGS2XDH
SCHEMBL30831939 0.79 ADORA3 (0.53) TYRPDE4DBCHEACHEIDO1
SCHEMBL4251925 0.74 PTPN1 (0.57) TYRPTPN1SOAT2PDE4DBCHE
SCHEMBL30637452 0.74 PDE4D (0.59) PTPN1SOAT2PDE4DBCHEACHE
SCHEMBL4254656 0.72 PTPN1 (0.56) TYRPTPN1SOAT2PDE4DBCHE
SCHEMBL29572212 0.72 ESR1 (0.56) TYRPTPN1SOAT2PDE4DBCHE
Sesalin SCHEMBL8993385 0.72 PDE4D (0.63) PTPN1PDE4D
Sesalin SCHEMBL29402981 0.72 PDE4D (0.63) PTPN1PDE4D
SCHEMBL24728286 0.72 PDE4D (0.50) PTPN1PDE4DXDHLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230012268-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2023-01-12 US claimed
EP-4072558-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR Buzzelet Development And Technologies Ltd (IL) 2022-10-19 EP claimed
US-20240344028-A1 Serum-free media for producing adipocytes for animal consumption Mosa Meat B.V. (NL) 2024-10-17 US disclosed
US-12102653-B2 Ligand regulated protein-protein interaction system ST. ANNA KINDERKREBSFORSCHUNG (AT) 2024-10-01 US disclosed
EP-4373918-A1 SERUM-FREE MEDIA FOR PRODUCING ADIPOCYTES FOR ANIMAL CONSUMPTION Mosa Meat B.V. (NL) 2024-05-29 EP disclosed
US-20240000841-A1 LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM ST ANNA KINDERKREBSFORSCHUNG (AT) 2024-01-04 US disclosed
US-11844813-B2 Ligand regulated protein-protein interaction system ST. ANNA KINDERKREBSFORSCHUNG (AT) 2023-12-19 US disclosed
WO-2023003471-A1 METHOD FOR PRODUCING CULTURED FAT FOR ANIMAL CONSUMPTION. Mosa Meat B.V. (NL) 2023-01-26 WO disclosed
WO-2023003470-A1 SERUM-FREE MEDIA FOR PRODUCING ADIPOCYTES FOR ANIMAL CONSUMPTION. Mosa Meat B.V. (NL) 2023-01-26 WO disclosed
US-20230012268-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2023-01-12 US disclosed
EP-4072558-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR Buzzelet Development And Technologies Ltd (IL) 2022-10-19 EP disclosed
US-20220041687-A1 A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) ST. ANNA KINDERKREBSFORSCHUNG (AT) 2022-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041687-A1 A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) CARS1, CD74, HAVCR2 TYR 3799/4885PTPN1 1563/4885SOAT2 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.